- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT06769048
Eine Studie zum Testen verschiedener Dosen von BI 1584862 bei Menschen mit einer ausgeprägten Form der altersbedingten Makuladegeneration (AMD), der sogenannten geographischen Atrophie
JADE: Phase-II-Studie bei Patienten mit geografischer Atrophie: Eine randomisierte, doppelmaskierte, placebokontrollierte Dosisfindungsstudie zur Bewertung der Wirksamkeit und Sicherheit von BI 1584862
This study is open to adults aged 50 years and older with geographic atrophy that was diagnosed by imaging of the retina. The purpose of this study is to find out whether a medicine called BI 1584862 improves the eyes in people with geographic atrophy and to find the most suitable dose.
This study has 4 treatment groups. Participants are put into groups randomly, which means by chance. Initially participants can join a BI 1584862 and a placebo group; then more participants are put randomly in 2 additional BI 1584862 groups and a placebo group.
Participants are in the study for 1 year. During this time, they visit the study site 13 times. At the visits, doctors check the severity of participants' eye disease and collect information on any health problems. They take detailed pictures of the back of the eye, the retina, with imaging methods called fundus autofluorescence (FAF), near-infrared reflectance (NIR), and optical coherence tomography (OCT). They measure areas of the retina that appear healthy (bright) or start to waste away (dark, atrophy). The changes over time are then compared between the treatment groups.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Studientyp
Einschreibung (Tatsächlich)
Phase
- Phase 2
Kontakte und Standorte
Studienorte
-
-
-
Arecibo, Puerto Rico, 00612
- Emanuelli Research & Development Center
-
-
-
-
Arizona
-
Gilbert, Arizona, Vereinigte Staaten, 85297
- Associated Retina Consultants
-
Phoenix, Arizona, Vereinigte Staaten, 85020
- Associated Retina Consultants, Ltd.
-
Phoenix, Arizona, Vereinigte Staaten, 85050
- Cameron Ria, LLC
-
Scottsdale, Arizona, Vereinigte Staaten, 85255
- Retina Macula Institute of Arizona
-
-
California
-
Beverly Hills, California, Vereinigte Staaten, 90211
- Retina-Vitreous Associates Medical Group
-
Glendale, California, Vereinigte Staaten, 91204
- Global Research Management
-
Huntington Beach, California, Vereinigte Staaten, 92647
- Retina Associates of Southern California
-
Modesto, California, Vereinigte Staaten, 95356
- Retinal Consultants Medical Group, Inc
-
Mountain View, California, Vereinigte Staaten, 94040
- Northern California Retina Vitreous Associates MedicalGroup, Inc.
-
Newport Beach, California, Vereinigte Staaten, 92663
- Eye Research Foundation
-
Poway, California, Vereinigte Staaten, 92064
- Retina Consultants of San Diego
-
Sacramento, California, Vereinigte Staaten, 95825
- Retinal Consultants Medical Group
-
Walnut Creek, California, Vereinigte Staaten, 94598
- Bay Area Retina Associates - Walnut Creek
-
-
Colorado
-
Denver, Colorado, Vereinigte Staaten, 80222
- Retina Specialists of Colorado Research, LLC
-
-
Connecticut
-
Greenwich, Connecticut, Vereinigte Staaten, 06830
- Coastal Eye Surgeons
-
-
Florida
-
Gainesville, Florida, Vereinigte Staaten, 32605
- Vitreo Retinal Associates - Gainesville
-
Miami, Florida, Vereinigte Staaten, 33143
- MedEye Associates
-
Pinellas Park, Florida, Vereinigte Staaten, 33782
- Eye Associates of Pinellas
-
Stuart, Florida, Vereinigte Staaten, 34994
- East Florida Eye Institute
-
Winter Haven, Florida, Vereinigte Staaten, 33880
- Center for Retina and Macular Disease
-
-
Georgia
-
Augusta, Georgia, Vereinigte Staaten, 30909
- Southeast Retina Center, PC
-
-
Illinois
-
Oak Park, Illinois, Vereinigte Staaten, 60304
- Illinois Retina Associates - Oak Park
-
-
Kentucky
-
Louisville, Kentucky, Vereinigte Staaten, 40206
- The Eye Care Institute
-
-
Maryland
-
Hagerstown, Maryland, Vereinigte Staaten, 21740
- Cumberland Valley Retina Consultants
-
-
Massachusetts
-
Boston, Massachusetts, Vereinigte Staaten, 02114
- Ophthalmic Consultants of Boston
-
-
Missouri
-
Columbia, Missouri, Vereinigte Staaten, 65212
- University of Missouri Health System
-
-
New Jersey
-
Teaneck, New Jersey, Vereinigte Staaten, 07666
- NJRetina
-
-
Oregon
-
Eugene, Oregon, Vereinigte Staaten, 97401
- Verum Research, LLC
-
Portland, Oregon, Vereinigte Staaten, 97221
- Retina Northwest
-
Portland, Oregon, Vereinigte Staaten, 97225
- EyeHealth Northwest
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Vereinigte Staaten, 19107
- Mid Atlantic Retina - Wills Eye Hospital
-
-
South Carolina
-
Charleston, South Carolina, Vereinigte Staaten, 29414
- Charleston Neuroscience Institute - Charleston
-
-
Tennessee
-
Nashville, Tennessee, Vereinigte Staaten, 37203
- Tennessee Retina
-
-
Texas
-
Austin, Texas, Vereinigte Staaten, 78750
- Austin Clinical Research, LLC
-
Beaumont, Texas, Vereinigte Staaten, 77707
- Retina Consultants of Texas - Beaumont
-
Dallas, Texas, Vereinigte Staaten, 75231
- Retina Foundation of the Southwest
-
Plano, Texas, Vereinigte Staaten, 75024
- Red River Research Partners, LLC - Plano
-
San Antonio, Texas, Vereinigte Staaten, 78240
- Retinal Consultants of San Antonio
-
Schertz, Texas, Vereinigte Staaten, 78154
- Retina Consultants of Texas - Schertz
-
The Woodlands, Texas, Vereinigte Staaten, 77384
- Retina Consultants of Texas-The Woodlands-67575
-
-
Virginia
-
Falls Church, Virginia, Vereinigte Staaten, 22042
- Emerson Clinical Research Institute
-
Lynchburg, Virginia, Vereinigte Staaten, 24502
- Piedmont Eye Center
-
-
Washington
-
Bellevue, Washington, Vereinigte Staaten, 98004
- Pacific Northwest Retina
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion criteria:
-
Men and women with at least 1 eye with geographic atrophy (GA) secondary to age-related macular degeneration (AMD) determined by fundus autofluorescence (FAF). The total size of all GA lesions in the study eye (as determined by the independent central reading center (CRC)) must be ≥1.25 mm^2 and ≤12.0 mm^2:
- If multiple lesions are present in the study eye, at least 1 lesion must have an area of ≥0.5 mm^2
- At least 1 GA lesion must be at least in part within a 1500 μm radius ring centered on the fovea
- The foveal center point must not be involved in any atrophic lesion
- Lesion(s) must reside completely within the FAF image
-
Best corrected visual acuity (BCVA) score of ≥50 letters in the study eye using the early treatment diabetic retinopathy study (ETDRS) chart (approximately equivalent to ≥20/100 on the Snellen chart).
-
Hyperautofluorescence of any pattern, as assessed by the CRC, must be present in the junctional zone of GA in the study eye.
-
Age ≥50 years.
-
Men must be willing and able to use contraception (condom, abstinence) to prevent pregnancy and/or exposure of an existing embryo or fetus to the investigational product. A female participant is eligible if she is not a woman of childbearing potential.
-
Signed informed consent consistent with International Conference of Harmonization-Good Clinical Practice (ICH GCP) guidelines and local legislation
Exclusion criteria:
-
Any history of, or evidence of, exudative age-related macular degeneration (eAMD) in the study eye.
-
Previously received treatment for GA in the study eye within 4 months or 5 half-lives, prior to baseline, whichever is longer.
-
Previously received an investigational medication (oral or intravitreal) for GA within 4 months or 5 half-lives prior to baseline, whichever is longer.
-
Additional eye disease in the study eye that could compromise BCVA or significantly impact retinal morphology:
- uncontrolled glaucoma, defined as a disk-to-cup ratio >0.8 or ocular hypertension with intra ocular pressure (IOP) >24 mmHg at screening visit, or use of >2 active IOP-lowering agents in the study eye
- clinically significant diabetic retinopathy or maculopathy in the opinion of the investigator
- history of high myopia, i.e. spherical equivalent of ≥8 diopters or axial length ≥27.2 mm. Note: if subject had prior cataract or refractive surgery, spherical equivalent should be evaluated with pre-operative refraction. If axial length measurement is not available in medical records and cannot be obtained at screening visit, assessment of high myopia can be made by investigator on clinical examination.
- anterior segment and vitreous abnormalities that would preclude adequate observation with SD-OCT in the opinion of the investigator
- other ocular conditions at the discretion of the investigator that might interfere with the outcome of the trial
-
Significant disease or other medical conditions (as determined by medical history, examination, and clinical investigations at screening) that may, in the opinion of the investigator result in any of the following:
- put the participant at risk because of participation in the study
- influence the results of the study
- cause concern regarding the participant's ability to comply with the protocol requirements or complete the trial as scheduled (e.g. chronic alcohol or drug abuse or any other condition that, in the investigator's opinion, makes the participant an unreliable trial participant)
-
Known hypersensitivity to any of the ingredients used in the investigational medicinal product (IMP) formulation, or any of the medications used.
-
Active intraocular inflammation in the study eye.
-
Active infectious conjunctivitis in either eye. Further exclusion criteria apply.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Vervierfachen
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Placebo-Komparator: Placebo-passendes BI 1584862
|
Placebo-matching BI 1584862 |
|
Experimental: BI 1584862 Dosis 1
|
BI 1584862 |
|
Experimental: BI 1584862 Dosis 2
|
BI 1584862 |
|
Experimental: BI 1584862 Dosis 3
|
BI 1584862 |
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Slope of change from baseline in square root transformed geographic atrophy (GA) area as measured by fundus autofluorescence (FAF) over a treatment period of up to 50 weeks (expressed in mm/year) in the study eye
Zeitfenster: Up to week 50.
|
mm is millimeters. |
Up to week 50.
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Auftreten von TEAES von der Arzneimittelverabreichung bis Woche 52
Zeitfenster: Bis Woche 52.
|
Bis Woche 52.
|
|
|
Änderung der partiellen Schwächung gegenüber dem Ausgangswert als Prozentsatz der Ellipsoidzone (EZ) im Makulabereich mit einer Dicke von <20 Mikrogramm (μm) bis Woche 50, beurteilt durch volumetrische optische Kohärenztomographie (OCT) am Studienauge
Zeitfenster: Bis Woche 50.
|
Bis Woche 50.
|
|
|
Veränderung der Quadratwurzel-transformierten geografischen Atrophie (GA)-Fläche gegenüber dem Ausgangswert, gemessen durch Fundus-Autofluoreszenz (FAF) in Woche 50 (ausgedrückt in mm) im Studienauge
Zeitfenster: Zu Studienbeginn und in Woche 50.
|
Zu Studienbeginn und in Woche 50.
|
|
|
Key secondary endpoint: Change from baseline in total attenuation as a percentage of the EZ at the macular area with a thickness of 0 μm up to week 50 assessed by volumetric OCT and EZ mapping in the study eye
Zeitfenster: Up to week 50.
|
EZ stands for ellipsoid zone. OCT stands for optical coherence tomography. |
Up to week 50.
|
|
Key secondary endpoint: Slope of change from baseline in square root transformed GA area as measured by OCT over a trial period of up to 50 weeks (expressed in mm/year) in the study eye
Zeitfenster: Up to week 50.
|
GA stands for geographic atrophy. OCT stands for optical coherence tomography. mm is millimeters. |
Up to week 50.
|
|
Occurrence of BCVA letter loss of ≥15 from baseline in the study eye as measured by standardized ETDRS chart for at least 2 consecutive visits between baseline and up to Week 50
Zeitfenster: Up to week 50.
|
ETDRS is early treatment diabetic retinopathy study. |
Up to week 50.
|
|
Change from baseline in best-corrected low luminance visual deficit (LLVD) score as measured in letters by ETDRS chart under low-luminance conditions at Week 50 in the study eye
Zeitfenster: At baseline and at week 50.
|
ETDRS is early treatment diabetic retinopathy study. |
At baseline and at week 50.
|
Mitarbeiter und Ermittler
Sponsor
Publikationen und hilfreiche Links
Nützliche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- 1484-0005
- U1111-1309-9115 (Registrierungskennung: WHO International Clinical Trials Registry Platform (ICTRP))
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
Once the criteria in section "Time Frame" are fulfilled, researchers can use the following link https://www.mystudywindow.com/msw/datasharing to request access to the clinical study documents regarding this study, and upon a signed "Document Sharing Agreement".
Furthermore, researchers can request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website.
IPD-Sharing-Zeitrahmen
One year after the approval has been granted by major Regulatory Authorities and after the primary manuscript has been accepted for publication, or after termination of the development program.
IPD-Sharing-Zugriffskriterien
For study documents - upon signing of a 'Document Sharing Agreement'.
For study data - 1. after the submission and approval of the research proposal (checks will be performed by the sponsor and/or the independent review panel, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a legal agreement.
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .